How I treat endocrine-dependent metastatic breast cancer

Estrogen receptor-positive (ER+)/HER2-negative (HER2−), the so-called luminal-type breast cancer, is the most frequent subset, accounting for around 70% of all breast cancer cases. Endocrine therapy (ET) combined with cyclin-dependent kinases (CDK) 4/6 inhibitors is the standard first option in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gombos, A., Goncalves, A., Curigliano, G., Bartsch, R., Kyte, J.A., Ignatiadis, M., Awada, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969253/
https://www.ncbi.nlm.nih.gov/pubmed/36806375
http://dx.doi.org/10.1016/j.esmoop.2023.100882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969253/
https://www.ncbi.nlm.nih.gov/pubmed/36806375
http://dx.doi.org/10.1016/j.esmoop.2023.100882

Ejemplares similares